Datasheet 2: Vitiligo - An Autoimmune Skin Disease and Its Immunomodulatory Therapeutic Intervention
December 2021
in “
OPAL (Open@LaTrobe) (La Trobe University)
”
Studysummary This review discusses recent advancements in targeted therapies for vitiligo, highlighting the therapeutic potential of JAK inhibitors and mesenchymal stem cell-derived extracellular vesicles, and reports no new clinical results. Our plain-language summary of this paper — not a Tressless recommendation.
Vitiligo is a chronic autoimmune skin disorder characterized by the loss of functional melanocytes, with immune T cells, particularly CD8+ cytotoxic T cells and regulatory T cells, playing a significant role in its pathogenesis. Recent advancements in understanding the disease have led to the development of targeted therapies, such as Janus kinase (JAK) inhibitors, which have shown therapeutic significance. Additionally, mesenchymal stem cells (MSCs) and their extracellular vesicles (EVs) have emerged as promising treatments due to their ability to regulate cytokine secretion and T-cell balance, offering anti-inflammatory effects. The document highlighted the progress in these therapies and emphasized the need for further research into vitiligo treatment.
